A personalized mRNA melanoma vaccine built for each patient’s tumor has delivered the first successful Phase 3 result for this kind of treatment. In the global INTerpath-001 trial, intismeran autogene plus Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone after surgery, with two-year recurrence-free rates of 82.2% versus 70.0%.
The detailed data were announced October 22, 2026, and presented October 24 during Presidential Symposium I at the ESMO Congress 2026 in Madrid (Presentation LBA1), selected for an official ESMO press briefing, and accepted for publication in The New England Journal of Medicine. The treatment is investigational, not FDA approved, and overall survival data are not yet mature.
What the Phase 3 Trial Found
INTerpath-001 was a randomized, double-blind, placebo and active comparator controlled trial in patients with completely resected stage IIB to IV cutaneous melanoma. The trial enrolled 1,137 patients who were randomized 2 to 1 after complete surgical removal of their melanoma.
- 757 patients received intismeran autogene (1 mg every three weeks for up to nine doses) plus pembrolizumab, known as Keytruda (400 mg every six weeks for up to nine cycles, about one year).
- 380 patients received placebo plus Keytruda on the same Keytruda schedule, for up to about 56 weeks or until recurrence, unacceptable toxicity, or treatment completion.
- The primary endpoint was recurrence-free survival, defined as time from randomization to any local, locoregional, regional, or distant recurrence or death from any cause, assessed by the investigator.
- Key secondary endpoints included distant metastasis-free survival, overall survival, safety, tolerability, and quality of life.
After a median follow up of 24.6 months, in the intention-to-treat population:
- Risk of recurrence or death was reduced by 42% with the combination versus Keytruda alone (hazard ratio 0.58, 95% confidence interval 0.45 to 0.75, two sided p less than 0.001).
- Risk of distant metastasis or death was reduced by 38% (hazard ratio 0.62, 95% confidence interval 0.45 to 0.85, two sided p equals 0.002).
- Two year recurrence-free survival was 82.2% (95% CI 79.3% to 84.8%) for intismeran plus Keytruda compared with 70.0% (95% CI 65.0% to 74.5%) for Keytruda alone. Median was not reached in either arm.
- Two year distant metastasis-free survival was 88.5% (95% CI 86.0% to 90.6%) versus 80.2% (95% CI 75.6% to 84.0%). Median was not reached in either arm.
Improvements were generally consistent across prespecified subgroups, according to the joint announcement of detailed INTerpath-001 recurrence and metastasis results. Overall survival data are not yet mature, but the companies reported a favorable trend for the combination. The study remains ongoing to evaluate overall survival and other endpoints.
How a Tumor Becomes a Personal Vaccine
A personalized cancer vaccine for melanoma is not an off the shelf shot. Intismeran autogene, also known as V940 or mRNA-4157, is an investigational mRNA based individualized neoantigen therapy jointly developed by Merck and Moderna.
The process starts with the patient’s own tissue:
- Researchers sequence DNA from the surgically removed tumor and compare it with normal DNA from the same person.
- Software identifies tumor specific mutations that create abnormal proteins called neoantigens, which healthy cells do not display.
- That mutational signature becomes a blueprint for a synthetic mRNA strand encoding up to 34 selected neoantigens.
- After injection, cells translate the mRNA instructions and present the neoantigen pieces to the immune system, training T cells to recognize residual melanoma cells carrying those same flags.
Keytruda is added to sustain that response. The drug is a PD-1 checkpoint inhibitor that blocks a brake on T cells, helping activated immune cells stay active against tumor cells. As the AACR explainer on the personalized mRNA vaccine Phase 3 success notes, the vaccine provides the target list while pembrolizumab helps keep the immune attack from switching off.
This is why doctors distinguish therapeutic vaccines from classic preventive shots. Our overview of upcoming cancer vaccines that could prevent millions of cases explains that HPV and hepatitis B vaccines block infections before cancer starts, while intismeran is given after a melanoma diagnosis and surgery to lower the chance that microscopic remaining cells grow back.
Who Was in the Trial
Understanding who was studied prevents overgeneralizing the 42% figure. INTerpath-001 enrolled adults with high-risk cutaneous melanoma that surgeons could completely remove.
- Stage: IIB, IIC, III, or IV with no evidence of disease after resection. Stage IIB and higher means thicker, ulcerated, node positive, or previously metastatic disease with elevated recurrence risk.
- Setting: adjuvant, meaning treatment after surgery when scans show no visible cancer, with the goal of delaying or preventing return.
- Design: global, randomized, double-blind, with 2 to 1 allocation to vaccine plus Keytruda versus placebo plus Keytruda. The trial identifier is ClinicalTrials.gov NCT05933577 for the INTerpath-001 study design.
- Timing: treatment for up to about one year, with median follow up of 24.6 months at the primary analysis.
The trial did not test the vaccine in people who never had melanoma, in unresected metastatic disease, or as a substitute for surgery. It also did not compare vaccine plus Keytruda given after surgery with immunotherapy given before surgery, an approach called neoadjuvant therapy that is increasingly used for eligible patients.
Why Benefit Grows After Six Months
One of the most discussed details is timing. During the first six months, efficacy looked similar between arms, with a hazard ratio of 0.99 for recurrence or death and 1.01 for distant metastasis or death. After six months, following completion of the intismeran immunization regimen, benefit widened sharply.
- In a prespecified sensitivity analysis from six months onward, intismeran plus Keytruda reduced risk of recurrence or death by 58% (piecewise hazard ratio 0.42, 95% CI 0.30 to 0.58).
- Risk of distant metastasis or death after six months was reduced by half (hazard ratio 0.50, 95% CI 0.34 to 0.73).
- In the modified intention-to-treat population that excluded participants who never received at least one dose of intismeran or placebo as planned, risk reductions were 49% for recurrence or death (HR 0.51) and 45% for distant metastasis or death (HR 0.55).
Investigators say the delay makes biological and logistical sense. Each vaccine must be custom manufactured from the patient’s sequencing data, a process that can take about six weeks, while Keytruda starts promptly. In this program the median time from surgery to first vaccine dose was reported as 64 days. The immune system then needs repeated doses to build a broad T cell response.
That pattern is important for interpreting headlines. The 42% figure reflects the overall effect across the full follow up period, including the early months before full immunity developed. It does not mean 42 of every 100 patients were cured, and it does not mean protection starts on day one.
Safety Profile: What Side Effects Looked Like
At ESMO, safety drew close attention because any adjuvant advance must balance added toxicity against lower recurrence risk. According to the primary release, the safety profile was generally consistent with prior studies of the combination, with no new safety signals observed.
- treatment-related adverse events occurred in 95.8% of patients receiving intismeran plus Keytruda (723 of 755 treated) versus 90.0% with Keytruda alone (342 of 380).
- Grade 3 to 5 treatment-related events occurred in 14.2% versus 13.4%, respectively.
- The most common events in the combination arm were fever in 52.2%, injection-site pain in 51.0%, and fatigue in 38.5%.
Clinicians interviewed after the release described the added events as largely flu-like and injection related, distinct from the immune related side effects that Keytruda and other checkpoint drugs can cause across organs. Detailed safety tables presented in Madrid and the forthcoming peer reviewed publication will allow fuller comparison, but the top line rates suggest the vaccine adds mainly low grade, manageable reactions for most patients rather than a large jump in severe toxicity.
What This Vaccine Is Not
Clear boundaries matter as much as the headline number.
- It is not a preventive shot for healthy people. You cannot get it to avoid ever developing melanoma, and it does not replace sun protection, skin checks, or early biopsy of suspicious moles.
- It is not yet approved or available. Intismeran remains investigational. Moderna has said it is finishing a filing with regulators with the aim of seeking full approval in 2027, but regulators have not authorized it and timelines can change.
- It does not yet prove longer life. Overall survival is immature and the trial continues. Recurrence free and distant metastasis-free survival are meaningful because distant spread to lung, liver, or brain drives most melanoma deaths, but longer follow up is needed to show whether earlier recurrence control translates into more cures.
- It is not a do it yourself mRNA recipe. Manufacturing requires tumor sequencing, neoantigen selection, individual mRNA synthesis under strict quality control, and administration alongside supervised immunotherapy.
Earlier excitement came in August 2026 when the companies announced the trial had met its endpoints without sharing numbers. Partial data then leaked on social media before the scheduled October 24 ESMO presentation, prompting early release of top line results on October 22. The presentation was delivered October 24 by study principal investigator Professor Georgina Long of Melanoma Institute Australia and the University of Sydney, with ESMO reporting most common events of fever in 52.2% versus 8.2% and injection-site pain in 51.0% versus 9.5%, all cause grade 3 or higher events in 23.6% versus 20.3%, and simultaneous discontinuation of both drugs due to an adverse event in 6.5% versus 5.3%. The full peer review process, including The New England Journal of Medicine publication, will provide independent scrutiny of methods and subgroup findings.
| Question | What INTerpath-001 shows | What remains unknown |
|---|---|---|
| Does it lower recurrence after surgery? | Yes, 42% lower risk of recurrence or death, 82.2% vs 70.0% recurrence-free at 2 years | Durability beyond 2 years, need for longer follow up |
| Does it lower distant spread? | Yes, 38% lower risk of distant metastasis or death, 88.5% vs 80.2% at 2 years | Whether this converts to overall survival benefit |
| Is it safe to add to Keytruda? | No new signals, severe related events 14.2% vs 13.4% | Rare longer term immune effects, quality of life details |
| Can healthy people get it? | No, studied only in resected stage IIB to IV melanoma | Whether similar designs work in other cancers or earlier stages |
Why It Matters Beyond Melanoma
Melanoma is the test case because it carries many mutations for the immune system to recognize, making it a logical first target for neoantigen vaccines. More than 338,000 new melanomas were diagnosed worldwide in 2024, and an estimated 112,000 new cases plus more than 8,500 deaths are projected in the United States in 2026 alone. Even after complete surgery, recurrence often appears within two-years and more than half of recurrences involve distant sites that are harder to treat.
The broader INTerpath program now includes nine Phase 2 and Phase 3 trials across tumor types and disease settings, including three ongoing Phase 3 trials in non-small cell lung cancer. Additional studies are exploring renal cell carcinoma, bladder cancer, pancreatic ductal adenocarcinoma in the adjuvant setting, and perioperative gastric and lung cancer approaches.
History urges cautious optimism. An earlier Phase 2b trial, KEYNOTE-942, showed a 44% reduction in recurrence risk at early analysis and about a 49% reduction with longer follow up, with five year data presented at ASCO 2026, but that study was smaller and not definitive on survival. Success in melanoma does not guarantee success in cancers with fewer mutations or more immunosuppressive environments, such as pancreatic cancer or glioblastoma. Manufacturing scale is another hurdle, since each dose is made to order and cannot be stockpiled like a conventional vaccine.
Still, specialists called INTerpath-001 the first Phase 3 demonstration that adding a personalized vaccine can meaningfully improve on Keytruda alone after resection, a milestone after decades of failed cancer vaccine attempts. Similar individualized approaches, such as the experimental breast cancer vaccine that eliminated cancerous cells in an early human test, show how the field is shifting from one-size-fits-all drugs toward immune training matched to each tumor.
Frequently Asked Questions
When will the melanoma vaccine be available?
There is no approved personalized mRNA melanoma vaccine yet. Moderna has said it is completing a regulatory filing with the goal of full approval in 2027, and the companies say they are engaging regulators. Actual availability depends on regulatory review, manufacturing scale up, and payer decisions.
Is the melanoma vaccine FDA approved?
No. As of the ESMO 2026 presentation, intismeran autogene remains investigational. Breakthrough or other expedited designations do not equal approval.
What is a personalized cancer vaccine?
It is a treatment made from the mutations unique to one patient’s tumor. Tumor and normal DNA are compared to pick neoantigens, synthetic mRNA encoding up to 34 of those targets is manufactured, and injection trains T cells to hunt cells displaying the same abnormal proteins, usually alongside an immunotherapy such as Keytruda that keeps the immune response active.
Who was eligible for the trial?
Patients with stage IIB to IV cutaneous melanoma that had been completely surgically removed, with no visible disease at randomization. The trial tested adjuvant therapy after surgery, not treatment for active unresectable tumors and not prevention in healthy people.
Does the 42% reduction mean I have a 42% chance of being cured?
No. It means the relative risk of recurrence or death during the study period was 42% lower with the combination than with Keytruda alone. In absolute terms, about 12 more of every 100 patients were alive without recurrence at two-years (82.2% versus 70.0%). Individual benefit depends on stage, biology, and follow up care.
What were the side effects?
The most common added effects were fever, injection-site pain, and fatigue. Severe treatment-related events were similar between arms, 14.2% with the combination versus 13.4% with Keytruda alone, with no new safety signals reported in the primary release.
The Bottom Line for Patients Right Now
For people facing high-risk melanoma surgery today, INTerpath-001 does not change immediate care. Standard options remain complete resection plus discussion of adjuvant Keytruda or other approved approaches, with clinical trial referral where appropriate.
What has changed is the outlook. A custom-built mRNA vaccine plus immunotherapy kept more patients free of recurrence and distant spread through two-years than immunotherapy alone, with a safety profile clinicians described as manageable. If peer review, longer follow up, and regulatory review confirm the signal, adjuvant care could shift from the same drug for everyone with high-risk disease toward a tumor-informed plan that teaches the immune system what to watch for.
That promise will be tested first in lung, bladder, kidney, and other cancers where INTerpath studies are already underway. For now, the Madrid results mark a genuine milestone: proof in a large randomized trial that personalization can improve on a modern immunotherapy standard, without overstating what an investigational treatment can offer before approval and mature survival data.
